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ABSTRACT: Despite their discovery in the early 20th century and intensive study over the last 20 years, nicotinic acetylcholine
receptors (nAChRs) are still far from being well understood. Only a few chemical entities targeting nAChRs are currently
undergoing clinical trials, and even fewer have reached the marketplace. In our efforts to discover novel and truly selective
nAChR ligands, we designed and synthesized a series of chiral cyclopropane-containing α4β2-specific ligands that display low
nanomolar binding affinities and excellent subtype selectivity while acting as partial agonists at α4β2−nAChRs. Their favorable
antidepressant-like properties were demonstrated in the classical mouse forced swim test. Preliminary ADMET studies and broad
screening toward other common neurotransmitter receptors were also carried out to further evaluate their safety profile and
eliminate their potential off-target activity. These highly potent cyclopropane ligands possess superior subtype selectivity
compared to other α4β2-nAChR agonists reported to date, including the marketed drug varenicline, and therefore may fully
satisfy the crucial prerequisite for avoiding adverse side effects. These novel chemical entities could potentially be advanced to the
clinic as new drug candidates for treating depression.

■

INTRODUCTION
Over the past two decades, nicotinic acetylcholine receptors
(nAChRs) have been investigated with the goal of developing
drugs that can potentially treat a variety of nervous system
disorders such as Alzheimer’s disease, Parkinson’s disease,
schizophrenia, pathological pain, nicotine addiction, and
depression.1−4 In vertebrates, nAChRs are pentameric ligandgated ion channel proteins that are composed of 17 known
homologous subunits (α1−α10, β1−β4, γ, δ, and ε) that are
expressed widely throughout the central and peripheral nervous
systems (CNS and PNS) and neuromuscular junctions. They
broadly participate in physiological and pathophysiological
processes by modulating the synaptic release of neurotransmitters such as dopamine (DA), serotonin (5-HT),
glutamate (Glu), acetylcholine (ACh), and γ-aminobutyric
acid (GABA) that are all involved in the aforementioned
diseases.
© 2011 American Chemical Society

There are 12 nAChR subunits expressed in the nervous
system (α2−α10 and β2−β4), and different combinations of
subunits allow the assembly of many functional pentamers
although the actual number of functional pentamers expressed
is far less than the theoretical number of possible combinations.
The predominant form of nAChRs in the CNS are heteromeric
α4β2*−nAChR complexes characterized by high-affinity ACh
binding and slow desensitization (the asterisk denotes the possible integration of other subunits into the pentamer). Homomeric α7−nAChRs, which are typified by low ACh affinity and
fast activation, are the other major component in the brain.
Ganglionic α3β4* nAChRs play a dominant role in the sensory
and autonomic ganglia as well as in subpopulations of neurons
in the brain and are frequently associated with adverse side
Received: August 30, 2011
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effects such as emesis and nausea.5,6 Less abundant in the brain
overall, but nevertheless concentrated in dopaminergic, pleasure−
reward centers putatively involved in mood and drug dependence,
are α6*−nAChRs.
It is now well established that the α4β2*−nAChRs have an
essential role in mediating nicotine’s rewarding properties,7,8
and it is hypothesized that they are also responsible for the antidepressant effects of nicotinic agents. This notion is supported
by the findings that knockout mice lacking the nAChR β2
subunit do not show any behavioral antidepressant response to
mecamylamine or amitriptyline and that nAChR α4 subunit
knock-in mice exhibit increased anxiety.9−11 Furthermore,
social defeat, a behavioral model of depression in rodents,
produced a robust increase in the expression of the nAChR β2
subunits in the brain.12 In addition, nicotinic ligands targeting
α4β2*−nAChRs may likewise be used to treat neuropathic pain
or attention deficit hyperactivity disorder (ADHD).4 Because
there is a great deal of conservation between the primary structures of the nAChR subtypes, the design of ligands selective for
α4β2−nAChRs over α3β4*−nAChRs provides a challenge but
not one that is insurmountable.
Among the natural nicotinic ligands and a number of synthetic small molecules that have been pharmacologically tested
as agents targeting brain α4β2−nAChRs, only a small fraction
have been advanced to preclinical studies and even fewer have
made it to clinical trials. Abbott Laboratories developed ABT089 (1), an α4β2−nAChR partial agonist that recently underwent clinical trials for the treatment of pediatric ADHD.
Whereas this drug was found to be safe and well tolerated, it
showed no significant difference from placebo in terms of
efficacy.13 Another compound, TC-5214 (2) from Targacept,
the S-enantiomer of mecamylamine, is now in phase III development as an adjunctive therapy for major depressive disorder
(MDD).14 Pfizer’s varenicline (3), an α4β2−nAChR partial
agonist and a full agonist at α7− and α3β4*−nAChR, is at
present the most successful synthetic small molecule on the
market for smoking cessation pharmacotherapy (Figure 1).15

onset of action compared to currently available therapeutics. In
pursuit of this goal, our group has identified sazetidine-A (4) as a
highly potent α4β2−nAChR partial agonist with excellent
selectivity over α3β4*−nAChRs.16,17 Compound 4 has been
shown to possess extremely promising antidepressant and
anxiolytic effects in rodent studies, including nicotine-like effects
in drug discrimination studies.18−20 In addition, analgesic effects
of compound 4, without any neurological side effects, have been
reported using the rat formalin model.21 However, the potential
metabolic liability of the acetylenic bond in compound 4, which
may be oxidized to generate a labile, highly reactive oxirene,
thereby possibly giving rise to toxicity, discouraged further
advancement of this compound down the drug discovery
pipeline.22 Novel ligands were, therefore, designed to avoid the
acetylene function while maintaining the important pharmacophoric elements of compound 4. For various reasons, we
considered replacement of the acetylene by a small and rigid
cyclopropane ring. Cyclopropanes widely occur in both natural
products and synthetic, biologically active compounds.23,24 A
cyclopropane ring in place of the acetylene group would not
only function as a spacer but also might be directly involved in
the ligand−receptor binding interaction. The rigid structure of
the cyclopropane would endow the ligand with a unique
restricted conformation in which the functional groups display
a particular arrangement and might more effectively interact
with the amino acid residues of the binding site of the target
receptor. Moreover, the chiral cyclopropane could also be used
to modify the areas of space accessible to the side chain
hydroxyl, with the goal to optimize its hydrogen bonding
interactions.25 In our previous studies on analogues of compound 4, we found that a side chain length of between 4 and 6
carbon atoms was optimal for biological activity.26 As our first
goal, we chose to synthesize a cyclopropane ligand bearing a
four-carbon side chain counting along the shortest path from
the pyridine ring to the hydroxyl group.
The syntheses of the chiral cyclopropane ligands 12a, 13a−
17a, and 19a are described in Scheme 1. 3,5-Dibromopyridine
(5) underwent Br displacement with benzyl alcohol, followed
by a Heck reaction with n-butyl acrylate using a recently described, phosphine-free protocol27 to afford the α,β-unsaturated
ester 6. Conversion of the ester group to the Weinreb amide28
using a standard procedure and subsequent Corey−Chaykowsky
cyclopropanation gave the racemic mixture of cyclopropanes 7,
which were then reduced to the corresponding alcohols in two
steps, followed by chiral resolution on a ChiralPak AD column to
give alcohols 8a and 8b in gram quantities with essentially 100%
ee values.29,30 The absolute configuration of the alcohol 8a was
determined by the X-ray crystallography of its derivative 9a,
which was obtained by subsequent oxidation and coupling with a
chiral Evans oxazolidinone.
The optically pure alcohol 8a was subjected to standard
Swern oxidation, Wittig reaction, and hydroboration to obtain
the chain-extended terminal alcohol 10a. Successive acylation
of the alcohol, removal of the benzyl group, and Mitsunobu
reaction to install the azetidine moiety furnished the
intermediate 11a after removal of the isobutyrate group. The
intermediate 11a was then converted to a carbamate using
various amines or phenyl isocyanate. Removal of the Boc group
from 11a or the carbamate intermediates gave the desired
products 12a and 13a−17a. The methyl ether analogue 19a
was prepared by a similar procedure in which the methoxy
group was introduced as a substituent in the Wittig reagent, and
unsaturation removed by catalytic hydrogenation. Compounds

Figure 1. Selected examples of synthetic nAChR ligands.

The emergence of compound 3 lends support to the use of
α4β2−nAChR partial agonists as clinical drugs to treat nervous
system diseases. However, peripheral and central side effects of
compound 3, such as nausea, gastrointestinal symptoms, changes
in mood, and, perhaps, suicidal ideation are most likely due to its
insufficient subtype selectivity,4 indicating that the nicotinic arena
is still rife with both opportunities and challenges.

■

RATIONAL DESIGN AND SYNTHESIS OF CHIRAL
CYCLOPROPANE NACHR LIGANDS
There is still a need for antidepressants that exhibit fewer side
effects, act pharmacologically in new ways, and that have a faster
718
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Scheme 1.a

12b and 19b, diastereoisomers of 12a and 19a, were synthesized from 8b by the same sequence of steps.

■

IN VITRO RADIOLIGAND BINDING AND
FUNCTIONAL STUDIES
The Ki values of all the synthesized cyclopropane compounds
were evaluated by [3H]epibatidine binding competition assays
at seven heterologously expressed rat nAChR subtypes. As shown
in Table 1, compound 12a with a (1S,2R)-configured cyclopropane ring exhibited subnanomolar binding affinity for both
the α4β2− (Ki = 0.1 nM) and α4β2*− (Ki = 0.5 nM) nAChRs,
thus having Ki values similar to those found for compound 4.
Compound 12a was approximately 7-fold more potent than its
diastereoisomer 12b at both the α4β2− and α4β2*−nAChRs
(12b: Ki = 0.7 and 3.7 nM, respectively). Similarly, the (1R,2S)configured ether analogue 19b was less active than 19a at both
the α4β2− (Ki = 0.6 vs 0.1 nM) and α4β2*−nAChR subtype
(Ki = 6.2 vs 0.3 nM). All four of these compounds demonstrated good selectivity for nAChRs containing β2 subunits
(α2β2−, α3β2−, α4β2−, and α4β2*−nAChRs), which are
associated with the regulation of dopamine release in the nucleus accumbens,31 over nAChRs containing β4 subunits (α3β4−,
α2β4−, and α4β4−nAChRs). Of considerable importance in the
identification of therapeutically useful nicotinic ligands is the
selectivity away from the α3β4−nAChR subtype. The α3β4−/
α4β2−nAChR Ki ratios of the two cyclopropane analogues
featuring the (1S,2R)-configuration, 12a and 19a, were 65200
and 100000, respectively, which are much higher than that of
nicotine (α3β4−/α4β2−nAChR = 53) or even compound 4
(α3β4−/α4β2−nAChR = 24000). Collectively, these outcomes
clearly suggest that the (1S,2R)-configuration of the cyclopropane ring improves subtype selectivity by conferring the
proper orientation to the side chain, thereby improving upon
the compounds’ affinity for the α4β2−nAChR.
Next, we derivatized the hydroxyl group with a variety of carbamate groups, a common functional group in medicinal
chemistry that has been successfully employed in the design of
other selective α4β2−nAChR ligands, in our efforts to further
optimize the side chain.32 The carbamate analogues 13a−17a,
which contain the preferred (1S,2R)-configured cyclopropane
ring, also exhibited subnanomolar to low nanomolar binding
affinities at both the α4β2− and α4β2*−nAChRs (Table 1).
Their binding preference for the β2- over the β4-containing

a

Reagents and conditions: (a) (i) BnOH, NaH, DMF, rt, (ii) n-butyl
acrylate, 1% Pd(OAc)2, 2% PhNHCONH2, K2CO3, 130 °C; (b) (i)
2N NaOH, MeOH/THF (1:1), rt, (ii) MeNH2+OMeCl−, EDCI,
DMAP, CH2Cl2, rt, (iii) Me3S(O)+I−, NaH, DMSO, rt; (c) (i) DIBALH, THF, −78 °C to −20 °C, (ii) NaBH4, MeOH, rt, (iii) Chiralpak
AD, EtOH; (d) (i) (COCl)2, DMSO, Et3N, CH2Cl2, −78 °C, (ii)
NaClO2, KH2PO4, 2-methyl-2-butene, tert-butanol/H2O, rt; (e) (i)
trimethylacetyl chloride, Et3N, THF, −78 to 0 °C, (ii) (S)-(+)-4phenyl-2-oxazolidinone lithium salt, THF, −78 to 0 °C; (f) (COCl)2,
DMSO, Et3N, CH2Cl2, −78 °C; (g) (i) Ph3PCH2, THF, 0 °C, (ii)
dicyclohexylborane, THF, 0 °C to rt, (iii) 30% H2O2, 3N NaOH,
55 °C; (h) isobutyric anhydride, cat. DMAP, Et3N, CH2Cl2, rt; (i) (i)
10% Pd/C, H2, EtOAc/MeOH, rt, (ii) 1-(tert-butoxycarbonyl)-(2S)azetidinylmethanol, azodicarbonyldipiperidide (ADDP), P(n-Bu)3,
PhMe, 0 °C to rt; (j) NaOMe, MeOH, 40 °C; (k) 1,1′-carbonyldiimidazole,
PhMe, THF, amine, rt, or phenyl isocyanate, PhMe, reflux; (l)
CF3COOH, CH2Cl2, rt; (m) Ph 3PCHOCH3, THF, 0 °C; (n)
PtO 2, H2, CH2Cl 2, rt.

Table 1. Binding Affinities of Cyclopropane Ligands, Nicotine, and Sazetidine-A at Seven nAChR Subtypes
Ki (nM)a
compd
12a
12b
13a
14a
15a
16a
17a
19a
19b
nicotined
4e

α2β2
0.1
0.5 ± 0.1
0.3 ± 0.1
0.3 ± 0.1
0.9 ± 0.1
1.5 ± 0.1
1.2 ± 0.1
0.1
0.5 ± 0.1
5.5

α2β4
c

249
65.0 ± 7
1890
261
720
2330
241
236
405
70

α3β2

α3β4

α4β2

3.0 ± 0.4
17.0 ± 7
9.8 ± 2.9
15.0 ± 2.1
16.0 ± 3
21.5 ± 5.2
24.4 ± 5.7
2.4 ± 0.4
20 ± 7.3
29

6520
1040
>10000
>10000
>10000
>10000
8850
>10000
>10000
260
10000

0.1
0.7 ± 0.1
0.6 ± 0.1
0.4
0.7 ± 0.1
0.8 ± 0.1
0.6 ± 0.1
0.1
0.6 ± 0.1
4.9
0.4

α4β2*b

α4β4

selectivity (α3β4/α4β2)

± 0.1
± 0.6
± 0.2
± 0.3
± 0.3
± 0.3
± 1.1
0.3
6.2 ± 1.6
9.8
0.9

82.6 ± 9
29.0 ± 4.3
441
281
234
162
551
50.2 ± 11
96.5 ± 21
23

65200
1500
>100000
>100000
>100000
>100000
14800
>100000
>16700
53
24000

0.5
3.7
1.7
2.1
2.4
4.0
5.9

a
See Experimental Section. bα4β2*, prepared from rat forebrain. cSEM values are not provided for Ki values >100 nM. dThe binding data
for nicotine are from the PDSP Assay Protocol Book (http://pdsp.med.unc.edu/). eThe binding data for compound 4 were obtained from
Reference 16.
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agonism EC50 values (Table 2). All tested ligands had neither
agonist nor antagonist activity at ganglionic α3β4*− or muscletype α1β1γδ−nAChRs even at the highest concentration
(10 μM) tested.
In the functional agonism studies, the efficacies of the tested
compounds were determined in a mixed population of high
sensitivity (HS) and low sensitivity (LS) α4β2−nAChRs. The
efficacy values at the HS α4β2−nAChRs were extrapolated
using compound 4 defined as a full agonist at the HS α4β2−
nAChR with 100% efficacy (see Supporting Information for
more details).20 All of the tested ligands were found to be
partial agonists at HS α4β2−nAChRs with efficacy values ranging from 60 to 92%.

nAChRs was consistent with that of the corresponding alcohols
and ethers. For both the α3β2− and α4β2*−nAChRs, binding
affinities gradually decreased as the size of substituents at the
carbamate nitrogen increased.
Additionally, radioligand competition binding assays revealed
the cyclopropane ligands tested (12a−17a, 19a, 12b, and 19b)
to have very low affinity for α7−nAChRs. Ten μM concentrations of test ligand inhibited binding of 10 nM 3H-epibatidine
by a maximum of 30% (16a) with other compounds showing
less inhibition or no inhibition of radioligand binding at all (data
not shown).
For functional studies, all compounds were tested in 86Rb+
ion flux assays using SH-EP1-hα4β2 cells, which heterologueously and stably express human α4β2−nAChRs assembled
from individual subunits.33,34 SH-SY5Y and TE671/RD cells
were used to assess activities of tested compounds at human
α3β4*− or α1β1γδ−nAChRs, respectively.35,36 All of the cyclopropane ligands had agonist activity at α4β2−nAChRs with
EC50 values <50 nM (Table 2). Consistent with the radioligand

■

IN VIVO BEHAVIORAL PHARMACOLOGY
To assess the antidepressant effects of selected compounds in vivo,
we used the mouse forced swim test,37 an assay in which mice are
placed into a beaker of water and the time the mouse spends
passively floating in the water (immobility) is recorded. Most
traditional antidepressants decrease the amount of time the mouse
spends immobile. Mice were administered the most potent
compounds 12a, 13a, and 19a, or the selective serotonin reuptake
inhibitor, sertraline, as a positive control (20 mg/kg) (Figure 2).
All of the three tested compounds exhibited antidepressantlike effects at the minimal dose of 10 mg/kg (compound 13a)
or 3 mg/kg (compounds 12a and 19a). Receptor occupancy
(RO) studies were also performed to quantify the relationship
between drug concentration at the receptor and the observed
antidepressant effects.38 When tested at a dose of 10 mg/kg,
both the compounds 12a and 19a showed very high levels of
ex vivo receptor occupancy (85−95%) at the β2* receptors,
whereas the carbamate analogue 13a showed only approximately 65% occupancy (Figure 3). These RO findings are

Table 2. Sensitivities and Efficacies of Ligand Agonism and
Inactivation at α4β2 nAChRsa
agonism

desensitization

compd

EC50
(nM)

efficacy
(%)b

efficacy (%)
HSc

IC50
(nM)

efficacy
(%)b

12a
12b
13a
14a
15a
16a
17a
19a
19b
nicotined
4d

10.2
34.6
15.7
18.2
23.3
44.4
48.9
17.5
43.1
290
5.8

21
10
17
15
27
23
24
6
8
88
55

92
65
77
71
80
69
78
60
62

9.4
50.9
18.2
19.1
19.6
48.5
50.2
5.6
50.4
430
4.8

63
69
85
85
82
84
87
71
75
93
63

100

a

See Experimental Section. bThe efficacies were measured in a mixture
of HS and LS α4β2-nAChRs. cThe efficacy values were extrapolated
using compound 4 defined as a full agonist at the HS α4β2-nAChR
(see Supporting Information for details). dResults for nicotine and
compound 4 were obtained from Reference 17.

binding studies, compounds 12a and 19a bearing the (1S,2R)configured cyclopropane ring exhibited about 3-fold higher
potencies than their diastereoisomers 12b and 19b (EC50: 10.2
vs 34.6 nM; 17.5 vs 43.1 nM). The functional agonism in the
carbamate series tended to decline stepwise with the increasing
size of the terminal substituents of the side chain. All compounds were found to functionally inactivate the response of
the α4β2−nAChRs to a full agonist at IC50 values similar to the

Figure 3. Receptor occupancy studies of compounds 12a, 13a, and
19a in mice showed a significant occupancy level. (*Mann−Whitney
U: p < 0.05). All drugs were injected intraperitoneally; n = 46/
group.

Figure 2. Mouse forced swim data for compounds 12a (A), 13a (B), and 19a (C). The selective serotonin reuptake inhibitor, sertraline, produced
the expected decrease in immobility. (ANOVAs: F (3,35) = 13.43, p < 0.001 (A); F (3,36) = 11.46, p < 0.001 (B); F (4,44) = 9.29, p < 0.001 (C).
*Fisher’s PLSD posthoc test: ps < 0.05 vs vehicle). All drugs were administered orally; n = 910/group.
720

dx.doi.org/10.1021/jm201157c | J. Med. Chem. 2012, 55, 717−724

Journal of Medicinal Chemistry

Article

subtype selectivity for α4β2−nAChRs. The best compounds,
12a, 13a, and 19a, exhibited subnanomolar to low-nanomolar
binding affinity for both α4β2− and α4β2*−nAChRs with
negligible interaction with α3β4−nAChRs. In functional
studies, these ligands acted as highly potent, partial agonists at
HS α4β2−nAChRs and were totally inactive at both ganglionic α3β4*− or muscle-type α1β1γδ−nAChRs. Compounds
12a, 13a, and 19a were found to display antidepressant-like
properties in the mouse forced swim test, associated with high
levels of β2* receptor occupancy. Furthermore, our findings
that these three compounds lack any significant off-target activities and show favorable ADMET profiles commend these
chiral cyclopropane ligands as potential drug candidates for the
treatment of depression.

consistent with their observed antidepressant potencies, with
compounds 12a and 19a being more potent and compound
13a being less potent (Figure 2).

■

BROAD SCREENING AND PRELIMINARY ADMET
STUDIES
Apart from assessment of ligand interactions with nAChRs, a
broad-ranging screen was carried out for compounds 12a, 13a,
and 19a to determine their off-target binding at 53 other neurotransmitter receptors and transporters that are widely
distributed throughout the CNS. The PDSP broad screening
studies indicated that none of the three tested compounds
showed significant interactions with other neurotransmitter
receptors and transporters (see Supporting Information for
more details).
Compounds 12a, 13a, and 19a were further tested in
preliminary ADMET assays.39 When incubated with human or
mouse liver microsomes, at least 80% of compound 12a, 98% of
compound 13a, or 84% of compound 19a remained unchanged
after 1 h incubation at 1 μM. In the presence of compounds
12a, 13a, or 19a at a concentrations up to 10 μM, none of the
CYP isoforms tested (CYP1A, CYP2C9, CYP2C19, CYP2D6,
and CYP3A) showed more than 25% inhibition, indicating
minimal adverse drug−drug interactions, with the exception of
compound 13a and 19a, which displayed about 80% and 70%
inhibition of the CYP1A2 isoform, respectively. The plasma
protein binding of compound 13a was investigated using
human and mouse plasma (CD-1) at 10 μM. A mean percent
binding of 8.4 and 23.8, respectively, was observed. Lastly,
automated patch-clamp electrophysiology was employed to
measure the inhibitory interactions between the test compounds
(12a, 13a, and 19a) and hERG K+ channels using CHO cell
lines in three test concentrations (0.1, 1, and 10 μM). At the
highest concentration, compounds 12a, 13a, and 19a exhibited
19.1%, 16.6%, and 13.7% inhibition of tail current, respectively,
indicating minimal potential for hERG-related cardiovascular
toxicity.
To further explore the metabolic stability of these cyclopropane ligands, compound 19a was selected for full mouse in
vivo pharmacokinetic (PK) studies. The plasma and brain
concentrations of compound 19a in male CD-1 mice after a
single oral gavage administration at a dose of 5 mg/kg were
measured. Compound 19a possessed a reasonable half-life in
brain (t1/2 = 150 min) as well as in plasma (t1/2 = 144 min).
The concentration of compound 19a reached a value of
133 ng/mL (Cmax‑brain) in 30 min (Tmax‑brain) in brain, and of
359 ng/mL (Cmax‑plasma) in 10 min (Tmax‑plasma) in plasma. The
brain to plasma ratio of compound 19a was found to be 0.37
(Cmax‑brain/Cmax‑plasma), indicating acceptable CNS penetration.
In contrast, brain exposure levels of compound 4 were relatively
low (∼3 ng/g at 1 mg/kg or ∼10 ng/g at 3 mg/kg) when
measured 15 min after administration and were at or below
detection level at later time points.38

■

EXPERIMENTAL SECTION

General. All chemicals were purchased from Sigma-Aldrich or ChemImpex, and solvents were used as obtained from Fisher Scientific or
Sigma-Aldrich without further purification. Anhydrous THF and CH2Cl2
were obtained by distillation over sodium wire or CaH2, respectively.
All nonaqueous reactions were run under an argon atmosphere with
exclusion of moisture from reagents, and all reaction vessels were
oven-dried. The progress of reactions was monitored by TLC on SiO2.
Spots were visualized by their quenching of the fluorescence of an
indicator admixed to the SiO2 layer or by dipping into I2/SiO2 mixture.
Products were purified by column chromatography on 230−400 mesh
SiO2. Proton and carbon NMR spectra were recorded at spectrometer
frequencies of 400 and 100 MHz, respectively. NMR chemical shifts
were reported in δ (ppm) using the δ 7.26 signal of CHCl3 (1H
NMR), the δ 4.80 signal of HDO (1H NMR), and the δ 77.23 signal of
CDCl3 (13C NMR) as internal standards. 13C NMR spectra in D2O
were not adjusted. Optical rotation was detected on an Autopol IV
automatic polarimeter. Mass spectra were measured in the ESI mode
at an ionization potential of 70 eV with an LC-MS MSD (HewlettPackard). The final compounds were purified by preparative HPLC,
which was carried out on an ACE 5 AQ column (150 mm × 20 mm),
with detection at 254 and 280 nm on a Shimadzu SPD-10A VP
detector; flow rate = 17.0 mL/min; gradient of 0−50% methanol in
water (both containing 0.05 vol% of CF3COOH) in 30 min. Purities
of final compounds (>98%) were established by both elemental
analysis and by analytical HPLC, which was carried out on an Agilent
1100 HPLC system with a Synergi 4 μm Hydro-RP 80A column, with
detection at 254 or 280 nm on a variable wavelength detector
G1314A; flow rate = 1.4 mL/min; gradient of 0−100% methanol in
water (both containing 0.05 vol% of CF3COOH) in 18 min. See
Supporting Information for detailed experimental procedures and
NMR spectral data (1H and 13C) of all intermediates.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-hydroxyethyl)cyclopropyl]pyridine Trifluoroacetate (12a). 1H NMR (D2O): δ
8.33 (s, 1H), 8.23 (s, 1H), 7.85 (s, 1H), 4.98 (m, 1H), 4.53 (d, J = 4.0
Hz, 2H), 4.17−4.07 (m, 2H), 3.71 (t, J = 6.4 Hz, 2H), 2.70 (q, J = 8.4
Hz, 2H), 1.98 (m, 1H), 1.68 (q, J = 6.8 Hz, 2H), 1.33 (m, 1H), 1.20−
1.14 (m, 2H). 13C NMR (D2O): δ 162.3 (TFA), 155.8, 146.3, 132.0,
128.0, 125.3, 115.9 (TFA), 67.1, 60.8, 58.2, 43.3, 35.1, 21.9, 19.8, 19.4,
16.3. [α] D 20 = +36.5 (c 0.40, MeOH). Anal. Calcd for
C14H20N2O2·2.15CF3COOH·0.5H2O: C, 43.74; H, 4.64; F, 24.39;
N, 5.57. Found: C, 43.55; H, 4.42; F, 24.38; N, 5.52.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1R,2S)-2-(2-hydroxyethyl)cyclopropyl]pyridine Trifluoroacetate (12b). 1H NMR (400 MHz,
D2O): δ 8.32 (s, 1H), 8.22 (s, 1H), 7.84 (s, 1H), 4.97 (m, 1H), 4.52
(d, J = 4.0 Hz, 2H), 4.16−4.06 (m, 2H), 3.70 (t, J = 6.4 Hz, 2H), 2.69
(q, J = 8.4 Hz, 2H), 1.97 (m, 1H), 1.67 (q, J = 6.8 Hz, 2H), 1.32
(m, 1H), 1.17−1.12 (m, 2H). 13C NMR (100 MHz, D2O): δ 162.3
(TFA), 155.8, 146.3, 132.0, 127.9, 125.3, 115.9 (TFA), 67.1, 60.8,
58.3, 43.3, 35.1, 21.9, 19.8, 19.4, 16.3. [α]D20 = −49.4 (c 0.17, MeOH).
Anal. Calcd for C14H20N2O2·2CF3COOH·0.15H2O: C, 45.13; H, 4.69;
F, 23.79; N, 5.85. Found: C, 45.10; H, 4.67; F, 23.90; N, 5.84.

■

CONCLUSION
In summary, a series of chiral cyclopropane analogues of the
lead structure, compound 4, were identified as highly potent,
α4β2-selective nAChR partial agonists. To avoid possible issues
relating to the metabolic instability of the acetylene bond, a
rigid cyclopropane ring was introduced in its place. The
cyclopropane ring is also virtuous because of its ability to direct
the orientation of the side chain in a manner that improves
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3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-[2-(Nmethylcarbamoyloxy)ethyl]cyclopropyl]pyridine Trifluoroacetate (13a). 1H NMR (D2O): δ 8.35 (s, 1H), 8.23 (s, 1H), 7.84
(s, 1H), 4.98 (m, 1H), 4.52 (d, J = 3.6 Hz, 2H), 4.27−4.05 (m, 4H),
2.70 (q, J = 8.4 Hz, 2H), 2.62 (s, 3H), 1.99 (m, 1H), 1.88 (m, 1H),
1.65 (m, 1H), 1.34 (m, 1H), 1.16 (m, 2H). 13C NMR (D2O): δ 162.3
(TFA), 159.2, 156.2, 146.5, 132.3, 128.2, 125.7, 115.9 (TFA), 67.5,
64.8, 58.6, 43.6, 32.6, 26.5, 22.3, 20.2, 19.8, 16.4. [α]D20 = +43.3
(c 0.18, MeOH). Anal. Calcd for C16H23N3O3·1.95CF3COOH·
1.8H2O: C, 42.67; H, 5.14; F, 19.84; N, 7.50. Found: C, 42.77; H,
4.99; F, 19.86; N, 7.35.
3-[(2( S )-Azetidinyl)methoxy]-5-[(1S,2R )-2-[2-( N,Ndimethylcarbamoyloxy)ethyl]cyclopropyl]-pyridine Trifluoroacetate (14a). 1H NMR (D2O): δ 8.31 (s, 1H), 8.19 (s, 1H), 7.80
(s, 1H), 4.94 (m, 1H), 4.48 (d, J = 4.0 Hz, 2H), 4.20−4.03 (m, 4H),
2.79 (s, 6H), 2.66 (q, J = 8.4 Hz, 2H), 1.95 (m, 1H), 1.83 (m, 1H),
1.65 (m, 1H), 1.33 (m, 1H), 1.11 (m, 2H). 13C NMR (D2O): δ 162.3
(TFA), 157.8, 155.9, 146.2, 131.9, 127.9, 125.3, 115.9 (TFA), 67.1,
65.0, 58.2, 43.2, 35.1, 32.2, 21.9, 19.8, 19.4, 16.3. [α]D20 = +31.3
(c 0.07, MeOH). Anal. Calcd for C17H25N3O3·2.15CF3COOH·1.55H2O:
C, 43.18; H, 5.15; F, 20.68; N, 7.09. Found: C, 43.35; H, 5.12; F, 20.51;
N, 6.89.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-[2-(Ncyclopropylcarbamoyloxy)ethyl]cyclopropyl]-pyridine Trifluoroacetate (15a). 1H NMR (D2O): δ 8.34 (s, 1H), 8.22 (s,
1H), 7.84 (s, 1H), 4.98 (m, 1H), 4.52 (d, J = 4.0 Hz, 2H), 4.19−4.05
(m, 4H), 2.69 (q, J = 8.4 Hz, 2H), 2.37 (m, 1H), 1.97 (m, 1H), 1.85
(m, 1H), 1.65 (m, 1H), 1.31 (m, 1H), 1.14 (m, 2H), 0.63 (m, 2H),
0.39 (m, 2H). 13C NMR (D2O): δ 162.3 (TFA), 159.3, 155.9, 146.2,
131.9, 128.0, 125.4, 115.9 (TFA), 67.2, 64.4, 58.2, 43.3, 32.1, 21.9,
21.8, 19.8, 19.4, 16.1, 5.3, 5.2. [α]D20 = +40.6 (c 0.68, MeOH). Anal.
Calcd for C18H25N3O3·1.95 CF3COOH·0.7H2O: C, 46.44; H, 5.05; F,
19.62; N, 7.42. Found: C, 46.19; H, 4.74; F, 19.42; N, 7.16.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-[2-(1pyrrolidinylcarbonyloxy)ethyl]cyclopropyl]-pyridine Trifluoroacetate (16a). 1H NMR (D2O): δ 8.32 (s, 1H), 8.20 (s, 1H), 7.81
(s, 1H), 4.95 (m, 1H), 4.49 (d, J = 4.0 Hz, 2H), 4.20−4.04 (m, 4H),
3.22 (m, 4H), 2.67 (q, J = 8.8 Hz, 2H), 1.94 (m, 1H), 1.87−1.76 (m,
5H), 1.66 (m, 1H), 1.33 (m, 1H), 1.11 (m, 2H). 13C NMR (D2O): δ
162.3 (TFA), 156.1, 155.9, 146.2, 131.9, 128.0, 125.3, 115.9 (TFA),
67.2, 64.7, 58.2, 45.5, 43.2, 32.2, 24.3, 21.9, 19.8, 19.4, 16.3. [α]D20 =
+39.7 (c 0.66, MeOH). Anal. Calcd for C19H27N3O3·2.25CF3COOH·
0.45H2O: C, 46.26; H, 4.98; F, 21.02; N, 6.89. Found: C, 46.11; H, 4.81;
F, 20.95; N, 6.91.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-[2-(Nphenylcarbamoyloxy)ethyl]cyclopropyl]pyridine Trifluoroacetate (17a). 1H NMR (D2O): δ 8.02 (s, 1H), 7.96 (s, 1H), 7.58 (s,
1H), 7.20 (t, J = 8.0 Hz, 2H), 7.07 (d, J = 7.6 Hz, 2H), 7.01 (t, J =
7.2 Hz, 1H), 4.41 (m, 1H), 4.21 (m, 1H), 4.10 (m, 3H), 3.97 (m, 1H),
2.59 (m, 2H), 2.02 (m, 1H), 1.83 (m, 1H), 1.45 (m, 1H), 1.28 (m,
1H), 1.04 (m, 2H). 13C NMR (D2O): δ 162.3 (TFA), 155.5, 154.9,
145.9, 137.2, 131.4, 128.6, 127.4, 125.0, 123.1, 118.1, 115.9 (TFA),
66.8, 64.1, 58.0, 43.2, 32.4, 21.7, 19.9, 19.8, 16.3. [α]D20 = +36.4
(c 0.91, MeOH). Anal. Calcd for C21H25N3O3·2.15CF3COOH·1.0H2O:
C, 48.19; H, 4.66; F, 19.43; N, 6.66. Found: C, 48.16; H, 4.51; F, 19.48;
N, 6.51.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (19a). 1H NMR (D2O): δ
8.35 (s, 1H), 8.24 (s, 1H), 7.86 (s, 1H), 5.00 (m, 1H), 4.54 (d, J = 4.0
Hz, 2H), 4.18−4.09 (m, 2H), 3.61 (t, J = 6.4 Hz, 2H), 3.36 (s, 3H),
2.71 (q, J = 8.4 Hz, 2H), 2.00 (m, 1H), 1.74 (m, 2H), 1.34 (m, 1H),
1.21−1.15 (m, 2H). 13C NMR (D2O): δ 162.3 (TFA), 155.9, 146.2,
132.0, 128.0, 125.4, 115.9 (TFA), 71.5, 67.1, 58.2, 57.3, 43.3, 32.2,
22.0, 19.8, 19.4, 16.2. [α]D20 = +40.0 (c 0.20, MeOH). Anal. Calcd for
C15H22N2O2·2.05CF3COOH·0.5H2O: C, 45.42; H, 5.00; F, 23.13; N,
5.55. Found: C, 45.43; H, 4.90; F, 23.05, N, 5.57.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1R,2S)-2-(2-methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (19b). 1H NMR (D2O): δ
8.31 (s, 1H), 8.20 (s, 1H), 7.82 (s, 1H), 4.96 (m, 1H), 4.50 (d, J = 4.0
Hz, 2H), 4.14−4.05 (m, 2H), 3.55 (t, J = 6.4 Hz, 2H), 3.31 (s, 3H),
2.67 (q, J = 8.4 Hz, 2H), 1.96 (m, 1H), 1.69 (m, 2H), 1.28 (m, 1H),

1.16−1.10 (m, 2H). 13C NMR (D2O): δ 162.3 (TFA), 155.8, 146.2,
131.9, 127.9, 125.3, 115.9 (TFA), 71.4, 67.1, 58.3, 57.3, 43.3, 32.2,
21.9, 19.8, 19.4, 16.2. [α]D20 = −42.9 (c 0.84, MeOH). Anal. Calcd for
C15H22N2O2·2.05CF3COOH·0.6H2O: C, 45.26; H, 5.02; F, 23.05; N,
5.53. Found: C, 45.22; H, 4.88; F, 22.91; N, 5.47.
In Vitro Studies. [3H]Epibatidine competition studies: For experimental details, please refer to the PDSP Web site http://pdsp.med.
unc.edu/ for all nAChR subtypes except α7. For assay at α7, membrane preparations from SH-EP1 cells heterologously expressing
human α7 nAChRs were used to test 10 μM concentrations of test
ligands in competition with 10 nM [3H]epibatidine with an experimental protocol similar to that utilized by the PDSP.33,34
Cell Lines and Culture. Cell lines naturally or heterologously
expressing specific, functional, human nAChR subtypes were used.
The human clonal cell line TE671/RD naturally expresses human
muscle-type α1*−nAChRs, containing α1, β1, γ, and δ subunits, with
function detectable using 86Rb+ efflux assays.36 The human neuroblastoma cell line SH-SY5Y naturally expresses autonomic α3β4*−
nAChRs, containing α3, β4, probably α5, and sometimes β2 subunits,
and also displays function detectable using 86Rb+ efflux assays.33 SHSY5Y cells also express homopentameric α7−nAChRs; however, their
function is not detected in the 86Rb+ efflux assay under the conditions
used. SH-EP1 human epithelial cells stably transfected with cDNAs
separately encoding human α4 or β2 subunits (SH-EP1-hα4β2 cells)
have been established and characterized with both ion flux and
radioligand binding assays.34 These cells thus express a mixture of socalled “high sensitivity” (HS) α4β2−nAChRs, having the presumed
subunit ratios of 2:3 α4:β2 and comparatively high sensitivity to
nicotinic agonists, and “low sensitivity” (LS) α4β2−nAChRs
presumably having a 3:2 ratio of α4:β2 subunits at which nicotinic
agonists have lower observed potency.17
TE671/RD, SH-SY5Y, and transfected SH-EP1 cell lines were
maintained as low passage number (1−26 from our frozen stocks)
cultures to ensure stable expression of native or heterologously
expressed nAChRs as previously described. Cells were passaged once a
week by splitting just-confluent cultures 1/300 (TE671/RD), 1/10
(SH-SY5Y), or 1/40 (transfected SH-EP1) in serum-supplemented
medium to maintain log-phase growth.
General Procedures for Behavioral Studies. Animals.
BALB/cJ male mice (8−10 weeks old at testing) were obtained
from Jackson Laboratory (Bar Harbor, ME, USA). Mice were housed
four to a cage in a colony room maintained at 22 ± 2 °C on a 12 h
light−dark cycle. All animal experiments were conducted in
accordance with the NIH Guide for the Care and Use of Laboratory
Animals and the PsychoGenics Animal Care and Use Committee.
Drugs. Compounds 12a, 13a, and 19a were synthesized according
to procedures described in the text, and sertraline was purchased from
Toronto Research Chemicals (Ontario, Canada). All compounds were
dissolved in injectable water and administered by oral gavage (PO) in
a volume of 10 mL/kg.
Mouse Forced Swim Test. Procedures were based on those previously described. Mice were individually placed into clear glass cylinders (15 cm tall ×10 cm diameter, 1 L beakers) containing 23 ± 1 °C
water 12 cm deep (approximately 800 mL). Mice were administered
vehicle, the SSRI sertraline (10 or 20 mg/kg; IP or PO) as a positive
control, or compounds 12a (PO), 13a (PO), and 19a (PO). Thirty
min after compound administration, mice were placed in the water,
and the time the animal spent immobile was recorded over a 6 min
trial. Immobility was defined as the postural position of floating in the
water.
Statistical Analysis. Data were analyzed with Analysis of Variance
(ANOVA) with Treatment Group (Vehicle, Sertraline, compounds
12a, 13a, and 19a) as the between group variable and total time
immobile in sec (over the 6 min trial) as the dependent variable.
Significant main effects were followed up with the post hoc Fisher’s
PLSD test.
β2*-nAChR ex Vivo Receptor Occupancy. Compounds 12a, 13a,
and 19a (10 mg/kg) or water were administered via intraperitoneal
injection 30 min before brain collection (the same time point as in
forced swim testing) for analysis of β2−nAChR occupancy in the
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thalamus (for compound 12a and 19a, n = 6; for compound 13a, n = 4)
as described before.38
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